¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"dominant autosomal gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • dominant trait
    ¿ì¼º¼ÒÁú
  • homozygous dominant
    µ¿Á¾Á¢Çտ켺-
  • incompletely dominant
    ºÒ¿ÏÀü¿ì¼º-
  • sex-linked dominant inheritance
    ¼º¿¬°ü¿ì¼ºÀ¯Àü
  • X-linked dominant inheritance
    X¿¬°ü¿ì¼ºÀ¯Àü
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • calcitonin gene-related peptide
    Ä®½ÃÅä´ÑÀ¯ÀüÀÚ°ü·ÃÆéƼµå
  • candidate gene
    Èĺ¸À¯ÀüÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dominant mutation
    ¿ì¼ºµ¹¿¬º¯ÀÌ
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • dominant species
    ¿ì¼ºÁ¾
  • dominant trait
    ¿ì¼º¼ÒÁú
  • homozygous dominant
    µ¿Á¾Á¢Çտ켺
  • sex-linked dominant inheritance
    ¼º¿¬°ü¿ì¼ºÀ¯Àü
  • additive gene
    »ó°¡À¯ÀüÀÚ
  • allelic gene
    ´ë¸³À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • complementary gene
    º¸Á·À¯ÀüÀÚ, »óÈ£º¸ÃæÀ¯ÀüÀÚ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ
  • cooperating gene
    Çùµ¿À¯ÀüÀÚ
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
  • apc gene
    APC À¯ÀüÀÚ(¡­ë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene amplification
    À¯ÀüÀÚ ÁõÆø
  • gene analyses
    À¯ÀüÀںм®
  • gene analysis
    À¯ÀüÀںм®(¡­ÝÂà°).
  • gene analysis
    À¯ÀüÀںм®.
  • gene cloning
    À¯ÀüÀÚŬ·Î´×
  • gene conversion
    À¯ÀüÀÚº¯È¯.
  • gene conversion
    À¯ÀüÀÚº¯È¯(ܨüµ).
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene conversion
    À¯ÀüÀÚÀüȯ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • autosomal recessive
    »ó¿°»öü¿­¼º(¡­æøßäô÷æëàõ)ÀÇ.
  • autosomal recessive disorders
    »ó¿°»öü ¿­¼ºÁúȯ(¡­Ö«àõòðü´)
  • autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemen
    »ó¿°»öü ¿­¼º ÀÌ¿µ¾ç¼º ¼öÆ÷¼º Ç¥Çǹڸ®Áõ
  • autosomal recessive ichthyosis
    »ó¿°»öü¿­¼º¾î¸°¼±
  • autosomal recessive inheritance
    »ó¿°»öü¼º ¿­¼ºÀ¯Àü(¡­æëàõë¶îî).
  • autosomal recessive traits
    »ó¿°»öü¿­¼ºÇüÁú.
  • autosomal trisomy
    »ó¿°»öü»ïü¼º(ß²ô÷àõ)
  • generalized autosomal recessive dystrophic epidermolysis bullosa
    Àü½Å¼º »ó¿°»öü ¿­¼º ÀÌ¿µ¾ç¼º ¼öÆ÷¼º Ç¥Çǹڸ®Áõ
  • pedigree pattern of autosomal recessive trait
    »ó¿°»öü¼º ¿­¼ºÇüÁúÀÇ °¡°èµµ(¡­æëàõû¡òõ¡­Ê«Í§Óñ).
  • dominant
    ¿ì¼º(éÐàõ)(ÀÇ).
  • dominant
    ¿ì¼ºÀÇ
  • dominant character
    ¿ì¼ºÇüÁú(¡­û¡òõ), Áö¹èÀû Ư¼º(ò¨ÛÕîÜ÷åàõ).
  • dominant complement
    ¿ì¼ºº¸Ã¼(¡­ÜÍô÷).
  • dominant cystoid macular dystrophy
    ¿ì¼º³¶Æ÷Ȳ¹ÝÀÌ¿µ¾ç(Áõ)
  • dominant dystrophic epidermolysis bullosa
    ¿ì¼º ÀÌ¿µ¾ç¼º ¼öÆ÷¼º Ç¥Çǹڸ®Áõ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • gene amplification
    À¯ÀüÀÚ ÁõÆø(ë¶îîí­ñòøë)
  • gene bank
    À¯ÀüÀÚ ÀºÇà(ë¶îîí­ëÞú¼)
  • gene cloning
    À¯ÀüÀÚ(ë¶îîí­) Ŭ·Î´×
  • gene cluster
    À¯ÀüÀÚ(ë¶îîí­) ¼ÛÀÌ
  • gene conversion
    À¯ÀüÀÚ Àüȯ(ë¶îîí­ï®üµ)
  • gene dosage
    À¯ÀüÀÚ ·®(ë¶îîí­Õá)
  • gene duplication
    À¯ÀüÀÚ º¹»ç(ë¶îîí­ÜÜÞÐ)
  • gene expression
    À¯ÀüÀÚ ¹ßÇö(ë¶îîí­Û¡úÞ)
  • gene family
    À¯ÀüÀÚ Á·(ë¶îîí­ðé)
  • gene frequence
    À¯ÀüÀÚ ºóµµ(ë¶îîí­ÞºÓø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ADVIRC autosomal dominant vitreo-retinochoroidopathy
AR   1) Aortic Regurgitation
    = AI
  Echo¼Ò°ß
 &...
ABPA actin-binding protein, autosomal form; allergic bronchopulmonary aspergillosis
AR absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista...
AROA autosomal recessive ocular albinism
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CADASIL Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy
AR Autosomal Recessive
AR-JP Autosomal recessive juvenile parkinsonism
ARPKD Autosomal recessive polycystic kidney disease
ARRP Autosomal recessive retinitis pigmentosa
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dominant receptor
    ¿ì¼º ¼ö¿ëü
  • dominant trait
    ¿ì¼º ¼ÒÁú
  • allelic gene
    ´ë¸³ À¯ÀüÀÚ
  • C-jun gene
    ¾¾-ÁØ À¯ÀüÀÚ
  • cancer suppressor gene
    ¾Ï ¾ïÁ¦ À¯ÀüÀÚ
  • contiguous gene syndrome
    Á¢Ã˼º À¯ÀüÀÚ ÁõÈıº
  • control gene
    Á¦¾î À¯ÀüÀÚ
  • duplicate gene
    Áߺ¹ À¯Àü ÀÎÀÚ
  • exaggeration gene
    °­Á¶ À¯ÀüÀÚ
  • fcc gene
    FCC À¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ À¯ÀüÀÚ, Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ
    ÀÌ½ÄµÈ Á¶Á÷À» ÀÚ±â Á¶Á÷ ¶Ç´Â ¿ÜºÎ Á¶Á÷À¸·Î ÀνÄÇÏ´Â À¯ÀüÀÚ.
  • Is gene
    Is À¯ÀüÀÚ
  • marker gene
    Ç¥Áö À¯ÀüÀÚ
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • mutable gene
    À̺¯ À¯ÀüÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
dominant idea An idea that governs all one's actions and thoughts.
(05 Mar 2000)
dominant inheritance dominance of traits
dominant lethal trait Trait, expressed in the phenotype if present in the genotype, that precludes having descendants. All such cases are necessarily sporadic and must represent new mutations as the usual methods of classical genetics provide no means of demonstrating any genetic component whatsoever, except for tenuous arguments such as advanced paternal age. Molecular biology may help although the methods may be tedious; if there is an epistatic gene that may mask the trait, the logic is more tractable, though complex.
(05 Mar 2000)
dominant oncogene <genetics, molecular biology, oncology> A gene that stimulates cell proliferation and can drastically increase the risk of cancer development when present in a single copy.
(09 Oct 1997)
dominant species <biology, ecology, zoology> For each stratum, dominant species are those that, when ranked in descending rank order and cumulatively totaled, immediately exceed 50 percent of the total dominance measure, plus any additional species comprising 20 percent or more of the total dominance measure for the stratum.
(09 Oct 1997)
dominant trait An outstanding mental or physical characteristic.
See: dominance of traits.
(05 Mar 2000)
allelic gene See: allele, dominance of traits.
(05 Mar 2000)
antibiotic resistance gene Genes in a microorganism which confer resistance to antibiotics, for example by coding for enzymes which destroy it, by coding for surface proteins which prevent it from entering the microorganism, or by being a mutant form of the antibiotic's target so that it can ignore it.
(09 Oct 1997)
bicoid gene A group of genes which are important to the proper development of the head and thorax in the embryo of the fruit fly Drosophila melanogaster.
(09 Oct 1997)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
calcitonin gene-related peptide <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response.
It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene.
The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion.
Acronym: CGRP
(05 May 2002)
cancer susceptibility gene tumour suppressor gene
rab gene 1. <molecular biology> One of the three main groups of ras like genes specifying small GTP-binding proteins (the others are ras and rho). Rab proteins are involved in vesicular traffic and seem to control translocation from donor to acceptor membranes.
2. <cell biology> Gene family in plants responsive to abscisic acid: encode proteins of 15-17 kD.
(18 Nov 1997)
pair rule gene <molecular biology> A segmentation gene, expressed sequentially between gap genes and segment polarity genes. In development of Drosophila, a set of about 8 genes that are expressed only in alternate segments (odd or even) of the developing embryo. Loss of function mutants thus lack alternate segments.
Examples: even skipped (eve), fushi tarazu (ftz), hairy.
(18 Nov 1997)
variable gene <molecular biology> Those regions in the amino acid sequence of both the heavy and the light chains of immunoglobulins where there is considerable sequence variability from one immunoglobulin to other of the same class, in contrast to constant sequence (C) regions. The V regions are associated with the antigen binding areas. They contain hypervariable regions of particularly high sequence diversity.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
  • regulator(regulatory) gene
    Á¶Àý(Á¦¾î)À¯ÀüÀÚ
  • restorer gene
    ȸº¹ À¯ÀüÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á